Welcome to our dedicated page for CTS SEC filings (Ticker: CTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how piezoelectric sensors and actuators move CTS Corporation’s revenue needle means diving into hundreds of technical pages. Whether you’re comparing defense contracts with medical-device demand or gauging foreign-exchange exposure, the data hides deep inside forms most investors skim. CTS Corporation SEC filings explained simply is exactly what busy analysts need—and exactly what Stock Titan delivers.
Our platform’s AI reads every submission the moment it hits EDGAR, so understanding CTS Corporation SEC documents with AI takes minutes, not afternoons. Need the latest CTS Corporation quarterly earnings report 10-Q filing? It’s condensed with revenue by end-market and margin drivers. Want immediate alerts on insider activity? CTS Corporation Form 4 insider transactions real-time appear in your dashboard as they post. The same engine decodes cash-flow tables, segment notes, and risk factors, turning them into clear CTS Corporation earnings report filing analysis.
Below are quick links to the disclosures investors search for most:
- CTS Corporation annual report 10-K simplified for full-year strategy signals
- CTS Corporation insider trading Form 4 transactions and CTS Corporation executive stock transactions Form 4 to spot buying or selling trends
- CTS Corporation proxy statement executive compensation to benchmark leadership incentives
- CTS Corporation 8-K material events explained for sudden contract wins or leadership changes
Every filing—from S-8 share plans to credit-agreement exhibits—arrives with real-time updates, AI-powered summaries, and expert context. Stock Titan transforms dense disclosures into actionable clarity, so you can act on sensor-segment metrics or insider trades before the market does.
CTS Corporation reported a leadership change in its senior management team. On November 21, 2025, Martin Baumeister notified the company that he will resign from his role as Senior Vice President, effective at the close of business on December 5, 2025. The company states that his resignation is a personal decision to pursue another opportunity outside CTS and is not due to any disagreement with the company.
Effective the same date, December 5, 2025, CTS has appointed Pratik Trivedi, currently a Senior Vice President, as its new Chief Operating Officer. Trivedi, age 46, joined CTS in April 2024 and previously held leadership roles at Eaton Corporation plc and Cummins, Inc. CTS states that it did not enter into any material new plan or contract, nor did it change his compensation or grant equity in connection with this COO appointment.
CTS Corporation entered into a new five-year unsecured Credit Agreement providing a $300 million revolving credit facility with a bank syndicate led by Wells Fargo. The new facility replaces the company’s prior $400 million unsecured credit facility, which was terminated on November 24, 2025, after using initial borrowings to repay $63.3 million outstanding under the prior agreement.
The facility includes $20 million swing line and letter of credit sublimits and a $150 million alternative currency sublimit. Interest rates vary by loan type and are based on benchmark rates plus a margin tied to CTS’s net leverage ratio, and a quarterly commitment fee applies to unused capacity. Key covenants require a net leverage ratio not greater than 3.5 to 1.0, with a temporary step-up to 4.25 to 1.0 allowed around certain large acquisitions, and an interest coverage ratio of at least 3.0 to 1.
CTS Corp (CTS) disclosed a director equity award on a Form 4. On 11/06/2025, a director acquired 3,500 shares of common stock at $0 (coded “A”). Following the transaction, the director beneficially owns 35,913 shares, held directly.
The filing notes these were restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.
CTS Corp (CTS) reported a director equity grant. On 11/06/2025, a director acquired 3,500 shares of common stock at $0 (code A), reported as a grant of restricted stock units.
The filing notes these RSUs vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date. After the transaction, the reporting person beneficially owns 12,200 shares, held directly.
CTS Corp (CTS) director Robert Profusek reported acquiring 3,500 shares of common stock on 11/06/2025 at $0. The award reflects restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director.
Following the transaction, Profusek beneficially owns 101,742 shares directly and 1,800 shares indirectly through a spouse. The filing was made by one reporting person.
CTS Corp reported an initial statement of beneficial ownership by a director. The filing lists 3,500 common shares held directly as of 11/06/2025. The footnote states that certain restricted stock units vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.
CTS Corporation (CTS)11/06/2025, a director acquired 3,500 shares at $0, reported as a grant tied to restricted stock units. The filing notes these RSUs vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.
Following the transaction, the reporting person beneficially owns 46,700 shares, held directly. No derivative securities were listed.
CTS Corporation (CTS) disclosed a Form 4 for director Amy M. Dodrill. On 11/06/2025, she acquired 3,500 shares of common stock at $0, reported as a grant of restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director. After this transaction, her beneficial ownership stands at 8,800 shares, held directly.
CTS Corp (CTS) director Donna Costello reported an equity award on a Form 4. On 11/06/2025, she acquired 3,500 shares of common stock at $0 (code A). Following the transaction, her beneficial ownership stands at 19,500 shares, held directly.
The filing notes these were restricted stock units that vest 100% on the first anniversary of the grant date, contingent on her continued service as a director through the vesting date.
CTS Corporation expanded its Board of Directors from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services and will join CTS’s Nominating, Governance and Sustainability Committee and Technology and Transactions Committee.
As a non-employee director, she will receive compensation consistent with other non-employee directors as described in the Company’s March 28, 2025 proxy statement. The Company reported no arrangements leading to her selection and no related person transactions requiring disclosure under Item 404(a). CTS will enter into its standard indemnification agreement with her, and a related press release was furnished as Exhibit 99.1 on November 6, 2025.
FAQ
What is the current stock price of CTS (CTS)?
What is the market cap of CTS (CTS)?
